Lyophilized MUST BE RECONSTITUTED

Meet Retatrutide, a GGG tri-agonist that uniquely targets GLP-1 and GIP receptors while also activating the glucagon receptor. Its actions on these receptors offer a comprehensive approach to research distinct from older GLP-1 agonists.

By working on all three receptors at the same time, Retatrutide allows researchers to study how different metabolic signals interact within the body. This combined activity helps scientists better understand how hormones involved in glucose control, energy use, and fat metabolism communicate with one another.

In research settings, Retatrutide provides a broader view of metabolic processes than compounds that act on only one receptor. The addition of glucagon receptor activation allows researchers to explore how energy is released and managed, while GLP-1 and GIP pathways support investigation into glucose handling and nutrient response. Studying these pathways together helps create a clearer picture of overall metabolic balance.

Because of this multi-receptor design, Retatrutide is commonly used in metabolic and endocrine research focused on energy regulation, insulin response, and body weight mechanisms. Its unique structure supports research into how the body adapts when multiple hormonal signals are activated at once.

This compound is provided strictly for research use only and is intended for laboratory and preclinical studies where consistency, accuracy, and controlled conditions are required.